The association between serum fructosamine and random spot urine fructose levels with the severity of non-alcoholic fatty liver disease – an analytical cross-sectional study
DOI:
https://doi.org/10.7196/SAMJ.2024.v114i6.1748Keywords:
NAFLD, FRUCTOSAMINE, ALANINE AMINO TRANSFERASE, PLATELETS, ULTRASOUND,Abstract
Background. Non-alcoholic fatty liver disease (NAFLD) in South Africa and Africa at large is considered a hidden threat. Our local population is burdened with increased metabolic risk factors for NAFLD. Our setting requires a reasonable approach to screen for and aid the diagnosis of NAFLD.
Objectives. To investigate serum fructosamine and random spot urine fructose levels as biomarkers for the screening, diagnosis and monitoring of NAFLD. The primary objective of this study was to compare serum fructosamine and random spot urine fructose levels between groups with different levels of NAFLD severity as measured by ultrasound. A secondary objective was to determine the association, if any, between serum transaminases, the aspartate aminotransferase (AST) to platelet ratio index (APRI) score, serum fructosamine and urine fructose in different groups with steatosis.
Methods. Using a cross-sectional study design, 65 patients with three different levels of NAFLD, as detected by imaging, were enrolled. The primary exposures measured were serum fructosamine with random spot urine fructose, and secondary exposures were the serum transaminases (AST and alanine aminotransferase (ALT)) and the APRI score. Patients identified at the departments of gastroenterology, general internal medicine and diagnostic radiology were invited to participate.
Results. There were 38, 17 and 10 patients with mild, moderate and severe steatosis, respectively. There was no significant difference between the groups regarding serum fructosamine, measured as median (interquartile range): mild 257 (241 - 286) μmol/L, moderate 239 (230 - 280) μmol/L and severe 260 (221 - 341) μmol/L, p=0.5; or random spot urine fructose: mild 0.86 (0.51 - 1.30) mmol/L, moderate 0.84 (0.51 - 2.62) mmol/L and severe 0.71 (0.58 - 1.09) mmol/L, p = 0.8. ALT (U/L) differed between groups: mild 19 (12 - 27), moderate 27 (22 - 33), severe 27 (21 - 56), p=0.03, but not AST (U/L) (p=0.7) nor APRI (p=0.9). Urine fructose and ALT were correlated in the moderate to severe steatosis group (R=0.490, p<0.05), but not in the mild steatosis group. Serum fructosamine was associated with age in the mild steatosis group but not the moderate-severe steatosis group (R=0.42, p<0.01).
Conclusion. Serum fructosamine and random spot urine fructose did not vary with the severity of NAFLD, indicating that they would not be useful biomarkers in this condition.
References
Paruk IM, Pirie FJ, Motala AA. Non-alcoholic fatty liver disease in Africa: A hidden danger. Glob Health Epidemiol Genom 2019;4:e3. https://doi.org/10.1017/gheg.2019.2
Nassir F, Rector RS, Hammoud GM, Ibdah JA. Pathogenesis and prevention of hepatic steatosis. Gastroenterol Hepatol 2015;11(3):167-175.
PoonawalaA,NairSP,ThuluvathPJ.Prevalenceofobesityanddiabetesinpatientswithcryptogenic cirrhosis: A case-control study. Hepatology 2000;32(4 Pt 1):689-692. https://doi.org/10.1053/ jhep.2000.17894
CaldwellSH,CrespoDM.Thespectrumexpanded:Cryptogeniccirrhosisandthenaturalhistoryofnon- alcoholic fatty liver disease. J Hepatol 2004;40(4):578-584. https://doi.org/10.1016/j.jhep.2004.02.013
Chan WK, Chuah KH, Rajaram RB, Lim LL, Ratnasingam J, Vethakkan SR. Metabolic dysfunction-
associated steatotic liver disease (MASLD): A state-of-the-art review. J Obes Metab Syndr
;32(3):197-213. https://doi.org/10.7570/jomes23052
Rinella ME, Lazarus JV, Ratziu V, et al. A multi-society Delphi consensus statement on new fatty liver
disease nomenclature. J Hepatol 2023;78(6):1966-1986. https://doi.org/10.1016/j.jhep.2023.06.003
Le MH, Yeo YH, Li X, et al. 2019 global NAFLD prevalence: A systematic review and meta-analysis.
Clin Gastroenterol Hepatol 2021;20(12):e28. https://doi.org/10.1016/j.cgh.2021.12.002
Kruger FC, Daniels C, Kidd M, et al. Non-alcoholic fatty liver disease (NAFLD) in the Western Cape:
A descriptive analysis. S Afr Med J 2010;100(3):168-171. https://doi.org/10.7196/samj.1422
Tendler DA. Pathogenesis of nonalcoholic fatty liver disease. UpToDate, 2022. https://www-uptodate- com.uplib.idm.oclc.org/contents/pathogenesis-of-nonalcoholic-fatty-liver-disease?search=nafld&topi
cRef=3625&source=see_link (accessed 6 August 2022).
Yu S, Li C, Ji G, Zhang L. The contribution of dietary fructose to non-alcoholic fatty liver disease. Front
Pharmacol 2021;12:783393. https://doi.org/10.3389/fphar.2021.783393
Ferraioli G, Soares Monteiro LB. Ultrasound-based techniques for the diagnosis of liver steatosis.
World J Gastroenterol 2019;25(40):6053-6062. https://doi.org/10.3748/wjg.v25.i40.6053
Yilmaz Y, Yonal O, Kurt R, Bayrak M, Aktas B, Ozdogan O. Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver
disease: APRI in chronic liver disease. Hepat Mon 2011;11(2):103-106.
SanyalAJ,ShankarSS,YatesKP,etal.Diagnosticperformanceofcirculatingbiomarkersfornon-alcoholic
steatohepatitis. Nature Med 2023;29(10):2656-2664. https://doi.org/10.1038/s41591-023-02539-6
Vorster PC. Standard Operating Procedure pamphlet. Procedure for quantitative urinary fructose determination. North West University Human Metabolomics Department, HM-MET-017-ver
-Procedure for quantitative urinary fructose determination, 28 May 2018.
Roche Diagnostics GmbH. Package insert. FRA fructosamine order information. GmbH RD. Cobas
Roche. Roche Diagnositics, 2015.
Melzi d’Eril GV, Bosoni T, Solerte SB, Fioravanti M, Ferrari E. Performance and clinical significance
of the new fructosamine assay in diabetic patients. Wien Klin Wochenschr 1990;180(Suppl 1):60-63. 17. RCoreTeam.R:Alanguageandenvironmentforstatisticalcomputing.R4.3.1ed.Vienna:RFoundation
for Statistical Computing, 2024.
Lee D, Chiavaroli L, Ayoub-Charette S, et al. Important food sources of fructose-containing sugars and
non-alcoholic fatty liver disease: A systematic review and meta-analysis of controlled trials. Nutrients
;14(14):2846. https://doi.org/10.3390/nu14142846
Chen X, Wu J, Li R, Wang Q, Tang Y, Shang X. The establishment of adult reference intervals on
fructosamine in Beijing. J Clin Lab Anal 2016;30(6):1051-1055. https://doi.org/10.1002/jcla.21979
Rich NE, Oji S, Mufti AR, et al. Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, severity, and outcomes in the United States: A systematic review and meta-analysis. Clin
Gastroenterol Hepatol 2018;16(2):198-210.e2. https://doi.org/10.1016/j.cgh.2017.09.041
Downloads
Published
Issue
Section
License
Copyright (c) 2024 H Kamuzinzi, M Kgomo, P Rheeder, N Dada, P Bester
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
